The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines

Now WHO experts annually formulates references on structure of both the 3rd, and 4 valent vaccines against influenza applied worldwide. The purpose of work was the assessment of averted costs due to influenza vaccination with trivalent and quadrivalent vaccines in different age groups. Material and methods. The analysis was carried out by a modeling from a societal perspective taking into account epidemiological data on the Russian Federation. Results. According to data on structure of the allocated influenza viruses in the Russian Federation for 2006-2015, at vaccination coverage of 40% of the population, replacement of trivalent vaccines with quadrivalent vaccines could prevent in addition during the season on average 604 cases of influenza per 100 thousand children aged up to 3 years, 736 cases per 100 thousand children at the age of 3–6 years, 613 cases per 100 thousand children aged from 7 up to 14 years, 106 cases per 100 thousand citizens at the age of 15– 64 years, 19 cases per 100 thousand citizens at the age of 65 years and older. In the whole population replacement of trivalent vaccines with quadrivalent vaccines would allow to prevent during the season on average 181 cases of influenza per 100 thousand citizens in addition. The averted cost is the greatest at vaccination of children of preschool and school age. In general, the volume of the costs averted when replacing trivalent vaccines with quadrivalent vaccines against influenza could be increased for 2006–2015 on average by 15,0%, and during separate seasons this increasing could be more. Replacement of a trivalent vaccines with quadrivalent vaccines could cause decrease in number of cases of influenza during the season by 265,8 thousand, and the costs averted could make 2,498 billion rubles. Conclusions. Influenza vaccination with quadrivalent vaccines can increase clinical effectiveness and costs averted in comparison with trivalent vaccines. Replacement of trivalent vaccines with quadrivalent vaccines can be the most significant at vaccination of children of preschool and school age, and also in adults from risk groups and elderly people. Economic and clinical advantages of quadrivalent vaccines in comparison with the trivalent vaccines depend on a share in the general structure of a case rate of the strains of influenza B which aren’t relating to the line included in the trivalent vaccine.